LAEKNA THERAPEUTICS
Laekna Therapeutics is a startup biotech company focusing on innovative drug discovery and development. Targeting large unmet medical needs, Laekna is dedicated to developing new therapies for cancer and liver diseases.
LAEKNA THERAPEUTICS
Industry:
Biotechnology
Founded:
2016-12-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.laeknatp.com
Total Employee:
1+
Status:
Active
Total Funding:
168 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Mobile Non Scaleable Content Nginx Euro Microsoft Azure DNS PHP DigiCert SSL Japanese Yen
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Current Employees Featured
Founder
Investors List
CS Capital
CS Capital investment in Series D - Laekna Therapeutics
Infinity Capital
Infinity Capital investment in Series D - Laekna Therapeutics
Yanchuang Capital
Yanchuang Capital investment in Series D - Laekna Therapeutics
Shenzhen Capital Group
Shenzhen Capital Group investment in Series C - Laekna Therapeutics
OrbiMed
OrbiMed investment in Series B - Laekna Therapeutics
GP Healthcare Capital
GP Healthcare Capital investment in Series B - Laekna Therapeutics
OrbiMed
OrbiMed investment in Series A - Laekna Therapeutics
Anlongmed Fund
Anlongmed Fund investment in Series A - Laekna Therapeutics
Official Site Inspections
http://www.laeknatp.com Semrush global rank: 8.76 M Semrush visits lastest month: 261
- Host name: 129.101.dsnet
- IP address: 120.136.129.101
- Location: China
- Latitude: 31.0449
- Longitude: 121.4012
- Timezone: Asia/Shanghai
More informations about "Laekna Therapeutics"
Laekna Therapeutics
Laekna Therapeutics receives IND approvals in China and US for phase Ib/III global multi-center clinical study of afuresertib in combination with fulvestrant for patients with hr+/her2- breast cancerSee details»
Laekna
Laekna Announces Robust Phase 1b data of LAE002 (afuresertib) for treatment of HR+/ HER2- Breast Cancer at ESMO Congress 2024See details»
About Laekna - ABOUT US - Laekna Therapeutics - en.laeknatp.com
Founded in December 2016, Laekna Therapeutics is an emerging innovative biotech company based in Zhangjiang Pharma Valley in Shanghai, China and New Jersey, USA.See details»
Laekna Therapeutics announces first patient enrolled in the clinical ...
Jun 25, 2021 · Laekna Therapeutics Announces First Patient Enrolled in the Clinical Trial of Innovative Combination Therapy for Triple-Negative Breast Cancer. - The 5-year survival rate …See details»
About Laekna - ABOUT US - Laekna
Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to patients with cancer, metabolic diseases and liver fibrosis around …See details»
Laekna Therapeutics - VentureRadar
Website: http://www.laeknatp.com/ Develops innovative treatments for cancer and metabolic diseases, focusing on breakthrough therapies to improve patient outcomes and quality of life. …See details»
Laekna Therapeutics - PitchBook
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules …See details»
Laekna Therapeutics - Crunchbase Company Profile & Funding
Laekna Therapeutics is a startup biotech company focusing on innovative drug discovery and development. Targeting large unmet medical needs, Laekna is dedicated to developing new …See details»
Laekna Launched the new domain name www.laekna.com - PR …
Feb 7, 2022 · SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct or indirect subsidiaries, including Laekna Therapeutics Shanghai …See details»
Laekna Therapeutics - PharmaBoardroom
Aug 20, 2019 · Laekna is a company full of energy and innovation. Our talented scientists strive to solve the biggest problems in healthcare and bring breakthrough medicines to patients. …See details»
Laekna - Overview, News & Similar companies | ZoomInfo.com
Jan 3, 2024 · Laekna contact info: Phone number: +86 2150716089 Website: www.laeknatp.com What does Laekna do? Laekna Therapeutics is a Shanghai, China-based clinical-stage …See details»
Investors - INVESTORS - Laekna Therapeutics - en.laeknatp.com
金浦产业投资基金管理有限公司. GP Healthcare Capital. 深圳市创新投资集团有限公司See details»
Laekna Therapeutics will present two clinical study results in ESMO …
Jul 26, 2021 · Shanghai, China and New Jersey, U.S., July 26, 2021 — Laekna Therapeutics, an emerging innovative pharma company based in China’s “Zhangjiang Pharma Valley” and New …See details»
Laekna Therapeutics Receives IND Approvals in China and US for …
Aug 27, 2021 · The detail Laekna Therapeutics information can be found from the website: http://www.laeknatp.com.See details»
Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer …
Mar 24, 2020 · Laekna Therapeutics Shanghai Co., Ltd. (Laekna) today announced a new agreement with Novartis giving the China-based biotech company exclusive global rights to …See details»
Laekna Therapeutics reported positive results in two clinical …
Sep 16, 2021 · Afuresertib (LAE002) is an oral, small molecule pan-AKT kinase inhibitor. Whereas LAE001 is the first CYP17 /CYP11B2 dual inhibitor globally. Results: As of …See details»
Laekna Therapeutics (Shanghai) Co., Ltd. - synapse.zhihuiya.com
Here we introduce LAE119, a potent and selective PARP1 inhibitor and PARP1-DNA trapper. It demonstrates more than a 1000-fold selectivity for PARP1 DNA trapping compared to PARP2. …See details»
Strategic Partners - PARTNERSHIPS - Laekna Therapeutics
Dr. Guy Rosenthal joined Laekna Therapeutics in 2021 as Vice President, Head of Corporate and Business Development. As part of leading the corporate and business development group, his …See details»
Laekna Therapeutics | CipherBio
Explore Laekna Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Laekna Therapeutics reported positive results in two clinical …
Sep 16, 2021 · LAE001 is the first CYP17A1/CYP11B2 dual inhibitor globally. Results: As of May 25, 2021, 27 pts (16, 5, 3, 3 pts in the 50, 75, 100 and 125 mg BID cohorts, respectively) …See details»